4-HPR联合DDP对卵巢癌细胞株SKOV3增殖抑制作用的实验研究
|
摘要
第一部分4-HPR联合DDP对卵巢癌细胞株增殖抑制作用的体外实验研究
目的：4-羟苯基维胺脂(N-4-hydroxyphenyl retinode,4-HPR)是一种全反式维甲酸的衍生物,实验研究和部分临床实验表明,它对各种肿瘤有化学预防和治疗双重作用；顺铂(cisi-platin,DDP)是卵巢癌常用的化疗药物,但因其毒副作用及其耐药等问题,临床应用受到限制。本研究探讨在体外环境下,4-羟苯基维胺酯(4-HPR)联合顺铂(DDP)对人卵巢癌细胞株SKOV-3增殖及凋亡的影响。
方法：4-HPR单药,DDP单药及4-HPR+DDP联合用药方式多种剂量分别干预人卵巢癌细胞株SKOV-3; MTT法检钡SKOV-3细胞增殖抑制率变化；中效原理法判断联合用药的相互作用；HOCHST和流式细胞单染和双染分析凋亡细胞比例。实验结果计量资料以均数±标准差表示。应用SPSS13.0统计分析软件进行t检验,P<0.05被认为差异有统计学意义。
结果：MTT检测方法结果：
1、两种药物单独使用时均具有剂量依赖性和时间依赖性。
2、DDP：药物作用48小时,各相邻药物浓度组之间,只有DDP20μM与DDP10μM浓度组之间有统计学差异(P<0.05)；药物作用72小时,从DDP2.5μM浓度组开始均与相邻药物浓度组之间有统计学差异。
3、4-HPR;药物作用48小时,各相邻药物浓度组之间,只有4-HPR20μM与4-HPR10μM浓度组之间有统计学差异；药物作用72小时,从4-HPR10μM至4-HPR20μM浓度组均与相邻药物浓度组之间有统计学差异。
4、两种药物联合应用后,根据中效浓度的计算,除4-HPR1μM+DDP5μM在48h的联合应用组外,在其余48h与72h的所有联合应用组,均CI<1,即两种药物联合应用产生了协同作用的效果。
HOECHST检测方法：
1)DDP与4-HPR在作用SKOV-3细胞株72h后,两种药物单独使用时,均具有剂量依赖性。
2)DDP与4-HPR的联合应用,根据中效浓度的计算,4-HPR5μM+DDP组和4-HPR10μM+DDP5μM组均为CI<1,即两种药物联合应用产生了协同作用的效果。
流式双染检测法结果：
1)DDP与4-HPR在作用SKOV-3细胞株72h后,两种药物单独使用时均具有剂量依赖性。
2)DDP与4-HPR的联合应用,根据中效浓度的计算,三组药物联合应用组均为CI<1,即两种药物联合应用产生了协同作用的效果。
流式单染检测法：
1)DDP与4-HPR联合应用组：DDP通过降低G1期细胞的比例,主要将细胞阻滞在G2期,抑制SKOV-3细胞的增殖,而4-HPR主要将细胞阻滞在S期和G2期。联合应用两种药物的效果综合了两种药物的单独作用效果。
结论：SKOV-3细胞在4-HPR5μM+DDP5μM和4-HPR10μM+DDP5μM联合作用72h后,能够产生明显的抑制增殖的作用,且作用协同,其中4-HPR的使用浓度越高,抑制效应越明显。
第二部分4-HPR联合DDP对卵巢癌移植瘤增殖抑制作用的体内实验研究
目的：建立人卵巢癌皮下移植瘤裸鼠模型,探讨4-HPR和DDP单独应用及联合应用对移植瘤的作用,进一步探讨其作用机制。
方法：先培养人卵巢癌细胞株SKVO-3,用细胞悬液接种法制备荷瘤鼠模型1只；再用套管针组织块接种法进行皮下接4-HPR组种,共接种30只裸鼠；观察成瘤情况；分组后腹腔分别给药：(1)对照组：生理盐水；(2)4-HPR组:8mg/kg;(3)顺铂组：3mg/kg;(4)联合用药组：4-HPR8mg/kg,4-HPR给药6小时后给顺铂3mg/kg,均为腹腔注射给药,一次注射剂量为0.2ml,每周两次,共三周。每周测量肿瘤长、短径,计算肿瘤体积,绘制肿瘤生长曲线,取瘤组织进行病理学检查；免疫组织化学S-P法检测瘤组织Caspase-3蛋白的表达；检测细胞凋亡率和细胞周期变化。
结果：用2.5×1010个/只细胞悬液接种成功制备荷瘤鼠一只,套管针皮下接种SKVO-3瘤块后,2～3天皮丘消平,约4～5天可见微小的肿瘤结节,接种成功率为100%。治疗结束时测移植瘤体积分别为4937.72±563.28mm3、3726.34±462.32mm3、2687.78±631.91mm3、1532.69±723.84mm3,抑瘤率分别为0.00%、30.21%、42.78%、61.37%。移植瘤体积,各处理组均小于对照组,联合用药组小于单药组,差异均有统计学意义(p<0.05)；肿瘤组织病理：剖视肿瘤,对照组大部分呈类圆形,有的肿瘤可见表面血管,颜色灰白,质地较硬。光镜下见,对照组肿瘤具有恶性肿瘤细胞的一般特性,还具有特征性的腺腔样结构。实验组见不同程度点、片状坏死,并有炎性细胞的浸润,以联合用药组最重。免疫组织化学法检测Caspase-3的变化,对照组、4-HPR组、顺铂组、联合用药组,结果用免疫组化评分(HIS)分别为：2.78±1.33、4.15±0.76、5.22±0.62、6.37±1.25,各组与对照组相比,联合用药组与单药组相比,差异均有统计学意义(p<0.05)。流式细胞术结果显示：对照组、4-HPR组、顺铂组、联合用药组,细胞凋亡率逐渐升高,分别为6.43±2.31%、14.75±4.32%、21.54±1.47%、25.76±3.42%,细胞周期Go/G1期细胞逐渐减少,G2/M期细胞逐渐增多,S期细胞变化不明显。
结论：4-HPR对SKVO-3细胞的增殖抑制作用呈时间-剂量依赖关系,4-HPR与顺铂联合应用可增强顺铂对SKVO-3细胞的增殖抑制作用。4-HPR可抑制SKVO-3细胞裸鼠移植瘤的生长,4-HPR与顺铂联合应用抑瘤效果增强。4-HPR可使SKVO-3细胞,细胞周期阻滞于G2/M期,诱导其凋亡,4-HPR与顺铂联合应用诱导SKVO-3细胞凋亡作用增强。4-HPR可通过增加Caspase-3蛋白的表达,增强SKVO-3细胞对顺铂的敏感性。
SECTION ONE:THE SYNERGISTIC EFFECTS OF4-HPR COMBINED WITH CISPLATIN ON THE PROLIFERATION AND APOPTOSIS OF HUMAN OVARIAN CARCINOMA SKOV-3IN VITRO
objective:N-4-hydroxyphenyl retinode (4-HPR) is a synthetic amide analogue of ATRA. It was reported that4-HPR could inhibit the growth of ovarian cancer cells in vitro. Cis-platinum (DDP) is a first choice chemical agent used in ovarian cancer chemo-therapy. To study the proliferation and apoptosis effects of combinative application of4-HPR and DDP on the human ovarian carcinoma SKOV-3
Methods:Human ovarian carcinoma SKOV-3cell lines were interfered by4-HPR groups, DDP groups and combinative groups of4-HPR and DDP. The inhibitory effects of4-HPR and DDP on the proliferation SKOV-3were evaluated by MTT assay. The median-effect principle was used to analyze the mechanisms of the inhibitory effect after exposure to the combinative application of4-HPR and DDP. Cell apoptosis was detected by flow cytometry. Datas were shown as means±SEM by using SPSS software(version13.0; Chicago, USA). Significant differences were considered at P<0.05.
Results:MTT:
1. It showes time-dose dependent when the two drugs used alone.
2. DDP:There are statistical differences only between DDP20μM and DDP10μM in each adjacent drug group after48hours. There are statistical differences from DDP2.5μM with their adjacent drug groups after72hours.
3.4-HPR:There are statistical differences only between4-HPR20μM and4-HPR10μM in each adjacent drug group after48hours. There are statistical differences from4-HPR10μM to4-HPR20μM with their adjacent drug group after72hours.
4. After the combination of two drugs, all the groups after48and72hours show CI<1except4-HPR1μM+DDP5μM after48hours.
HOECHST:
1. Both DDP and4-HPR have a dose-dependent manner when used72hours.
2. DDP with4-HPR in combination, according to the calculation of the moderate effective concentration, Both4-HPR5μM+DDP5μM group and4-HPR10μM+DDP5μM group show CI<1, In other words, the combination of two drugs produces a synergistic effect.
Streaming double staining method:
1. Both DDP and4-HPR have a dose-dependent manner when used72hours.
2. DDP with4-HPR in combination, according to the calculation of the moderate effective concentration, the three groups of drug combination group were CI<1, in other words, the combination of two drugs produces a synergistic effect.
Streaming single dye detection method:
DDP with the combination of4-HPR group:DDP by reducing the proportion of cells in G1phase, inhibit the proliferation of SKOV-3cells through the cell cycle arrest in the G2phase;4-HPR arrest the cell in the S and G2phase. Two drugs have additive effect.
Conclusion:4-HPR5μM+DDP5μM and4-HPR10μM+DDP5μM significantly inhibited proliferation of ovarian cancer SKOV-3cells after72hours, and the effect is synergistic. The intensity increased with the concentration of4-HPR increased.
SECTION TWO:THE SYNERGISTIC EFFECTS OF4-HPR COMBINED WITH CISPLATIN ON THE PROLIFERATION AND APOPTOSIS OF HUMAN OVARIAN CARCINOMA SKOV-3IN VIVO
Objective. To establish the tumor-bearing nude mice models for human ovarian cancer, exam the effect of the application of4-HPR, DDP and combination of both4-HPR and DDP on transplanted tumor for further discussion of its mechanism of action.
Methods. In preparation of the tumor-bearing mice model, the human epithelial ovary cancer cell line SKVO-3which we fostered in advance was vaccinated to the nude mice using the cell suspension method.30mice were subcutaneously vaccinated with4-HPR using the trocar tissue block inoculation method. They were subsequently divided into groups and treated with medicine separately according to the formation of the tumor:(1) Control group:physiological saline;(2)4-HPR group:8mg/kg;(3) Cisplatin group:3mg/kg;(4) Combined treatment group:3mg/kg of cisplatin6hours after8mg/kg of4-HPR, both treated with intraperitoneal injection,0.2ml each time, twice a week for3weeks, the size of the tumor was measured every week and the tumor formation curve was graphed, tumor was removed for histopathological analysis; the expression of caspase-3was detected by immunohistochemical S-P method; the apoptosis rate and the periodic change of the cells were also detected.
Results. The mouse which was vaccinated with2.5×1010per mouse dosage cell suspension was successfully produced,2-3days after being subcutaneously vaccinated with SKVO-3tissue block, the ridge disappeared, tiny tumor nodules could be observed, the vaccination was successful. By the end of the treatment, the volumes of transplanted tumor were:4937.72±563.28mm3,3726.34±462.32mm3,2687.78±631.91mm3and1532.69±723.84mm3, the inhibition rates were:0.00%,30.21%,42.78%and61.37%. The sizes of the transplanted tumor in groups which were treated were significantly smaller than the size of the one in the control group; the transplanted tumor size in the combined treatment group was smaller than the one in single treatment groups, all differences have statistical significance(p<0.05); the histopathological analysis of the tumor tissue: according to the section view, the majority appeared to be round and tough grey surface vessels were observed. Through the light microscope, the tumor in control group demonstrated the general characters of malignancy and the distinctive structure of glandular cavity. Punctiform, flake necrosis emerged in in experimental groups with the infiltration of inflammatory cells, this phenomenon was most significant in the combined treatment group. Caspase-3which was examined by the immunohistochemical method for control group,4-HPR group, Cisplatin group and combined treatment group the IHS was:2.78±1.33,4.15±0.76,5.22±0.62and6.37±1.25. The differences among groups have statistical significance. The flow cytometry illustrated that the cell apoptosis rate in all groups gradually raised to6.43±2.31%,14.75±4.32%,21.54±1.47%and25.76±3.42%, G0/G1period cells reduced while the amount of G2/M period cells increased, and S period cells remained the same amount.
conclusion.The4-HPR inhibition of SKVO-3cells proliferation illustrated its dependence on time and dosage, and the combined treatment of4-HPR and cisplatin demonstrated enhanced suppression on the formation of SKVO-3cells.4-HPR can block SKVO-3cells in the G2/M period and lead them to apoptosis and the effect is more efficient with cisplatin.4-HPR has the potential to improve the caspase-3expression and increase the sensitivity of SKVO-3cells to cisplatin.
目的：4-羟苯基维胺脂(N-4-hydroxyphenyl retinode,4-HPR)是一种全反式维甲酸的衍生物,实验研究和部分临床实验表明,它对各种肿瘤有化学预防和治疗双重作用；顺铂(cisi-platin,DDP)是卵巢癌常用的化疗药物,但因其毒副作用及其耐药等问题,临床应用受到限制。本研究探讨在体外环境下,4-羟苯基维胺酯(4-HPR)联合顺铂(DDP)对人卵巢癌细胞株SKOV-3增殖及凋亡的影响。
方法：4-HPR单药,DDP单药及4-HPR+DDP联合用药方式多种剂量分别干预人卵巢癌细胞株SKOV-3; MTT法检钡SKOV-3细胞增殖抑制率变化；中效原理法判断联合用药的相互作用；HOCHST和流式细胞单染和双染分析凋亡细胞比例。实验结果计量资料以均数±标准差表示。应用SPSS13.0统计分析软件进行t检验,P<0.05被认为差异有统计学意义。
结果：MTT检测方法结果：
1、两种药物单独使用时均具有剂量依赖性和时间依赖性。
2、DDP：药物作用48小时,各相邻药物浓度组之间,只有DDP20μM与DDP10μM浓度组之间有统计学差异(P<0.05)；药物作用72小时,从DDP2.5μM浓度组开始均与相邻药物浓度组之间有统计学差异。
3、4-HPR;药物作用48小时,各相邻药物浓度组之间,只有4-HPR20μM与4-HPR10μM浓度组之间有统计学差异；药物作用72小时,从4-HPR10μM至4-HPR20μM浓度组均与相邻药物浓度组之间有统计学差异。
4、两种药物联合应用后,根据中效浓度的计算,除4-HPR1μM+DDP5μM在48h的联合应用组外,在其余48h与72h的所有联合应用组,均CI<1,即两种药物联合应用产生了协同作用的效果。
HOECHST检测方法：
1)DDP与4-HPR在作用SKOV-3细胞株72h后,两种药物单独使用时,均具有剂量依赖性。
2)DDP与4-HPR的联合应用,根据中效浓度的计算,4-HPR5μM+DDP组和4-HPR10μM+DDP5μM组均为CI<1,即两种药物联合应用产生了协同作用的效果。
流式双染检测法结果：
1)DDP与4-HPR在作用SKOV-3细胞株72h后,两种药物单独使用时均具有剂量依赖性。
2)DDP与4-HPR的联合应用,根据中效浓度的计算,三组药物联合应用组均为CI<1,即两种药物联合应用产生了协同作用的效果。
流式单染检测法：
1)DDP与4-HPR联合应用组：DDP通过降低G1期细胞的比例,主要将细胞阻滞在G2期,抑制SKOV-3细胞的增殖,而4-HPR主要将细胞阻滞在S期和G2期。联合应用两种药物的效果综合了两种药物的单独作用效果。
结论：SKOV-3细胞在4-HPR5μM+DDP5μM和4-HPR10μM+DDP5μM联合作用72h后,能够产生明显的抑制增殖的作用,且作用协同,其中4-HPR的使用浓度越高,抑制效应越明显。
第二部分4-HPR联合DDP对卵巢癌移植瘤增殖抑制作用的体内实验研究
目的：建立人卵巢癌皮下移植瘤裸鼠模型,探讨4-HPR和DDP单独应用及联合应用对移植瘤的作用,进一步探讨其作用机制。
方法：先培养人卵巢癌细胞株SKVO-3,用细胞悬液接种法制备荷瘤鼠模型1只；再用套管针组织块接种法进行皮下接4-HPR组种,共接种30只裸鼠；观察成瘤情况；分组后腹腔分别给药：(1)对照组：生理盐水；(2)4-HPR组:8mg/kg;(3)顺铂组：3mg/kg;(4)联合用药组：4-HPR8mg/kg,4-HPR给药6小时后给顺铂3mg/kg,均为腹腔注射给药,一次注射剂量为0.2ml,每周两次,共三周。每周测量肿瘤长、短径,计算肿瘤体积,绘制肿瘤生长曲线,取瘤组织进行病理学检查；免疫组织化学S-P法检测瘤组织Caspase-3蛋白的表达；检测细胞凋亡率和细胞周期变化。
结果：用2.5×1010个/只细胞悬液接种成功制备荷瘤鼠一只,套管针皮下接种SKVO-3瘤块后,2～3天皮丘消平,约4～5天可见微小的肿瘤结节,接种成功率为100%。治疗结束时测移植瘤体积分别为4937.72±563.28mm3、3726.34±462.32mm3、2687.78±631.91mm3、1532.69±723.84mm3,抑瘤率分别为0.00%、30.21%、42.78%、61.37%。移植瘤体积,各处理组均小于对照组,联合用药组小于单药组,差异均有统计学意义(p<0.05)；肿瘤组织病理：剖视肿瘤,对照组大部分呈类圆形,有的肿瘤可见表面血管,颜色灰白,质地较硬。光镜下见,对照组肿瘤具有恶性肿瘤细胞的一般特性,还具有特征性的腺腔样结构。实验组见不同程度点、片状坏死,并有炎性细胞的浸润,以联合用药组最重。免疫组织化学法检测Caspase-3的变化,对照组、4-HPR组、顺铂组、联合用药组,结果用免疫组化评分(HIS)分别为：2.78±1.33、4.15±0.76、5.22±0.62、6.37±1.25,各组与对照组相比,联合用药组与单药组相比,差异均有统计学意义(p<0.05)。流式细胞术结果显示：对照组、4-HPR组、顺铂组、联合用药组,细胞凋亡率逐渐升高,分别为6.43±2.31%、14.75±4.32%、21.54±1.47%、25.76±3.42%,细胞周期Go/G1期细胞逐渐减少,G2/M期细胞逐渐增多,S期细胞变化不明显。
结论：4-HPR对SKVO-3细胞的增殖抑制作用呈时间-剂量依赖关系,4-HPR与顺铂联合应用可增强顺铂对SKVO-3细胞的增殖抑制作用。4-HPR可抑制SKVO-3细胞裸鼠移植瘤的生长,4-HPR与顺铂联合应用抑瘤效果增强。4-HPR可使SKVO-3细胞,细胞周期阻滞于G2/M期,诱导其凋亡,4-HPR与顺铂联合应用诱导SKVO-3细胞凋亡作用增强。4-HPR可通过增加Caspase-3蛋白的表达,增强SKVO-3细胞对顺铂的敏感性。
SECTION ONE:THE SYNERGISTIC EFFECTS OF4-HPR COMBINED WITH CISPLATIN ON THE PROLIFERATION AND APOPTOSIS OF HUMAN OVARIAN CARCINOMA SKOV-3IN VITRO
objective:N-4-hydroxyphenyl retinode (4-HPR) is a synthetic amide analogue of ATRA. It was reported that4-HPR could inhibit the growth of ovarian cancer cells in vitro. Cis-platinum (DDP) is a first choice chemical agent used in ovarian cancer chemo-therapy. To study the proliferation and apoptosis effects of combinative application of4-HPR and DDP on the human ovarian carcinoma SKOV-3
Methods:Human ovarian carcinoma SKOV-3cell lines were interfered by4-HPR groups, DDP groups and combinative groups of4-HPR and DDP. The inhibitory effects of4-HPR and DDP on the proliferation SKOV-3were evaluated by MTT assay. The median-effect principle was used to analyze the mechanisms of the inhibitory effect after exposure to the combinative application of4-HPR and DDP. Cell apoptosis was detected by flow cytometry. Datas were shown as means±SEM by using SPSS software(version13.0; Chicago, USA). Significant differences were considered at P<0.05.
Results:MTT:
1. It showes time-dose dependent when the two drugs used alone.
2. DDP:There are statistical differences only between DDP20μM and DDP10μM in each adjacent drug group after48hours. There are statistical differences from DDP2.5μM with their adjacent drug groups after72hours.
3.4-HPR:There are statistical differences only between4-HPR20μM and4-HPR10μM in each adjacent drug group after48hours. There are statistical differences from4-HPR10μM to4-HPR20μM with their adjacent drug group after72hours.
4. After the combination of two drugs, all the groups after48and72hours show CI<1except4-HPR1μM+DDP5μM after48hours.
HOECHST:
1. Both DDP and4-HPR have a dose-dependent manner when used72hours.
2. DDP with4-HPR in combination, according to the calculation of the moderate effective concentration, Both4-HPR5μM+DDP5μM group and4-HPR10μM+DDP5μM group show CI<1, In other words, the combination of two drugs produces a synergistic effect.
Streaming double staining method:
1. Both DDP and4-HPR have a dose-dependent manner when used72hours.
2. DDP with4-HPR in combination, according to the calculation of the moderate effective concentration, the three groups of drug combination group were CI<1, in other words, the combination of two drugs produces a synergistic effect.
Streaming single dye detection method:
DDP with the combination of4-HPR group:DDP by reducing the proportion of cells in G1phase, inhibit the proliferation of SKOV-3cells through the cell cycle arrest in the G2phase;4-HPR arrest the cell in the S and G2phase. Two drugs have additive effect.
Conclusion:4-HPR5μM+DDP5μM and4-HPR10μM+DDP5μM significantly inhibited proliferation of ovarian cancer SKOV-3cells after72hours, and the effect is synergistic. The intensity increased with the concentration of4-HPR increased.
SECTION TWO:THE SYNERGISTIC EFFECTS OF4-HPR COMBINED WITH CISPLATIN ON THE PROLIFERATION AND APOPTOSIS OF HUMAN OVARIAN CARCINOMA SKOV-3IN VIVO
Objective. To establish the tumor-bearing nude mice models for human ovarian cancer, exam the effect of the application of4-HPR, DDP and combination of both4-HPR and DDP on transplanted tumor for further discussion of its mechanism of action.
Methods. In preparation of the tumor-bearing mice model, the human epithelial ovary cancer cell line SKVO-3which we fostered in advance was vaccinated to the nude mice using the cell suspension method.30mice were subcutaneously vaccinated with4-HPR using the trocar tissue block inoculation method. They were subsequently divided into groups and treated with medicine separately according to the formation of the tumor:(1) Control group:physiological saline;(2)4-HPR group:8mg/kg;(3) Cisplatin group:3mg/kg;(4) Combined treatment group:3mg/kg of cisplatin6hours after8mg/kg of4-HPR, both treated with intraperitoneal injection,0.2ml each time, twice a week for3weeks, the size of the tumor was measured every week and the tumor formation curve was graphed, tumor was removed for histopathological analysis; the expression of caspase-3was detected by immunohistochemical S-P method; the apoptosis rate and the periodic change of the cells were also detected.
Results. The mouse which was vaccinated with2.5×1010per mouse dosage cell suspension was successfully produced,2-3days after being subcutaneously vaccinated with SKVO-3tissue block, the ridge disappeared, tiny tumor nodules could be observed, the vaccination was successful. By the end of the treatment, the volumes of transplanted tumor were:4937.72±563.28mm3,3726.34±462.32mm3,2687.78±631.91mm3and1532.69±723.84mm3, the inhibition rates were:0.00%,30.21%,42.78%and61.37%. The sizes of the transplanted tumor in groups which were treated were significantly smaller than the size of the one in the control group; the transplanted tumor size in the combined treatment group was smaller than the one in single treatment groups, all differences have statistical significance(p<0.05); the histopathological analysis of the tumor tissue: according to the section view, the majority appeared to be round and tough grey surface vessels were observed. Through the light microscope, the tumor in control group demonstrated the general characters of malignancy and the distinctive structure of glandular cavity. Punctiform, flake necrosis emerged in in experimental groups with the infiltration of inflammatory cells, this phenomenon was most significant in the combined treatment group. Caspase-3which was examined by the immunohistochemical method for control group,4-HPR group, Cisplatin group and combined treatment group the IHS was:2.78±1.33,4.15±0.76,5.22±0.62and6.37±1.25. The differences among groups have statistical significance. The flow cytometry illustrated that the cell apoptosis rate in all groups gradually raised to6.43±2.31%,14.75±4.32%,21.54±1.47%and25.76±3.42%, G0/G1period cells reduced while the amount of G2/M period cells increased, and S period cells remained the same amount.
conclusion.The4-HPR inhibition of SKVO-3cells proliferation illustrated its dependence on time and dosage, and the combined treatment of4-HPR and cisplatin demonstrated enhanced suppression on the formation of SKVO-3cells.4-HPR can block SKVO-3cells in the G2/M period and lead them to apoptosis and the effect is more efficient with cisplatin.4-HPR has the potential to improve the caspase-3expression and increase the sensitivity of SKVO-3cells to cisplatin.
引文
[1].连利娟主编.林巧稚妇科肿瘤学.第三版.北京：北京人民卫生出版社,2002.405.
[2].糜若然,瞿全新主编.妇科肿瘤基因诊断与治疗.北京：人民卫生出版社,2001.304-305.
[3]. Hermiston T. Gene delivery from replication-selective viruses:aiming guided missiles in the war against cancer. J Clin Invest,2000,105(9):1169-1172.
[4]. Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer:primary and interval cytoreductive surgery [J]. Semin Oncol,1998,25(3): 326-334.
[5]. Mondimore FM, Fuller GA, DePaulo JR, Jr. Drug combinations for mania. J Clin Psychiatry.2003;64 Suppl 5:25-31.
[6]. Curatolo M, Sveticic G. Drug combinations in pain treatment:a review of the published evidence and a method for finding the optimal combination. Best Pract Res Clin Anaesthesiol.2002 Dec;16(4):507-519.
[7]. Kim KK, Lange TS, Singh RK,et al. Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide,5-fluorouracil and mitomycin C. BMC Cancer.2012,13(12):147-151.
[8]. Braga PC, Ricci D, Dal Sasso M. Daptomycin morphostructural damage in Bacillus cereus visualized by atomic force microscopy J Chemother.2002 Aug;14(4):336-341.
[9]. Paul TR, Venter A, Blaszczak LC, Parr TR, Jr., Labischinski H, Beveridge TJ. Localization of penicillin-binding proteins to the splitting system of Staphylococcus aureus septa by using a mercury-penicillin V derivative. J Bacteriol.1995 Jul;177(13):3631-3640
[10]. Illuzzi G, Bernacchioni C, Aureli M, et,al. Sphingosine kinase mediates resistance to the synthetic retinoid N-(4-hydroxyphenyl)retinamide in human ovarian cancer cells. J Biol Chem.2010,285(24):18594-602.
[11]. Rokoss MJ, Teo KK. Ramipril in the treatment of vascular diseases. Expert Opin Pharmacother.2005 Sep;6(11):1911-1919.
[12]. Sanchez-Martin M. Brain tumour stem cells:implications for cancer therapy and regenerative medicine.Curr Stem Cell Res Ther,2008,3(3):197-207.
[13]. Campo-Paysaa F, Marletaz F, Laudet V, et al. Retinoic acid signaling in development:tissue-specific functions and evolutionary origins.Genesis,2008,46 (11):640-656.
[14]. Lin LM, Li BX, Xiao JB, et al. Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis inhuman hepatoma, breast cancer, and lung cancer cells in vitro.World J Gastroenterol,2005,11 (36):5633-5637.
[15].Voigt A, Zintl F. Effects of retinoic acid on proliferation, apoptosis, cytotoxicity, migration, and invasion of neuroblastoma cells. Med PediatrOncol,2003,40(4) 205-213.
[16]. Zhang Y, Jia S, Liu Y, et al. A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl MedCommun,2007,28(4): 251-255.
[17]. Kast R E. Potential for all-trans retinoic acid (tretinoin) to enhance interferon-alpha treatment response in chronic myelogenous leukemia, melanoma, myeloma and renal cell carcinoma.Cancer Biol Ther,2008,7 (10):1515-1519.
[18]. Hail NJ,Lotan R. Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl) retinamide. Bio Chem, 2001,276(49):45 614-45621.
[19]. Elmore E, Luc TT, Steele VE, et al. Comparative tissue specific toxicities of 20 cancer p reventive agents using cultured cells from 8 different normal human epithelia. In V itrM ol Toxicol,2001,14 (3):191-207.
[20]. Eyou WANG, Jun Li, Guohm YANG, et al. Impact of 4HPR on the expression of E-Cad in human bladder transitional epithelial cancer cells T24[J]. Huazhong Univ Sci Tcchnol[Med Sci],2012,32(2):237-241.
[21]. Hail NJ, Lotan R. Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl)retinamide[J]. Bio Chem. 2001276(49):45614-21.
[22]. Valsecchi M, Aureli M, Mauri L, et al. Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids. J Lipid Res. 2010,51(7):1832-40..
[23]. Golubkov V, Garcia A, Markland FS. Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells. Anticancer Res,2005,25 (1A):249-253.
[24]. Cuello M, Coats AO, Darko I, et al. N-(4-hydroxyphenyl) retinamide (4-HPR) enhances TRAIL mediated apoptosis through enhancement of a mitochondrial dependent amplification loop in ovarian cancer cell lines. Cell Death Differ,2004,11 (5):527-541.
[25]. Ohlmann CH, Jung C, Jaques G. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-4-hydroxyphenyl) retinamide] sufficient for cancer therapy?.Int J Cancer,2002,100 (5):520-526.
[26]. Zou CP, Kurie JM, Lotan D, et al. Higher potency of N-(4-hydroxy-phenyl) retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res,1998,4 (5):1345-1355.
[27]. Pasctto LM, D'Andrea MR,Brandes AA, et al.The development of platinum compounds and their possible combination[J].Crit Rev Oncol Hematol.2006,60(1): 59-75.
[28]. Shimada K, Nakamura M, Isida, et al. Requirement of c-jun for testosterone-induced sensitization to N-(4-hydroxyphenyl)retinamide-induced apoptosis[J]. Mol Carcinog. 2003,36(3):115-22.
[29]. Chou TC.Theoretical basis, experimental design,and computedzexl simulation of synergism and antagonism in drug combination studies [J].Pharmacol Rev.2006, 58(3):621-681
[30]. Edinger AL, Thompson CB. Death by design:apoptosis, necrosis and autophagy[J]. Curr Opin Cell Biol.2004,16(6):663-669.
[1]. Jemal A,Siegel R,Ward E, et al. Cancer statistics[J]. CA Cancer J Clin,2006,56: 106-130.
[2]. Crawford R. Gynecologic oncology:current diagnosis and treatment. The New England Journal of Medicine,1996,25:203.
[3]. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer:a meta analysis [J]. Gynecol Oncol,2006, 103(3):1070-1076.
[4]. Daniel GR,Yang G,Liu GZ, et al. Ovarian cancer:pathology,biology,and disease models[J]. Front Biosci,2010,14:2089-2102.
[5]. Markman M. Management of oVarian cancer. An impressive history,of improvemention suvivial and quality of life[J]. Oncology(Williston Park),2006,20(4): 347-354
[6].吴令英.卵巢恶性肿瘤治疗进展[J].中国临床肿瘤学教育,2007：437-439。
[7]. Fu X, Hofman RM. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens [J]. Anticancer Res,1993,13:283-286.
[8]. Kiguchi K,Kubota T,Aoki D,et al. A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer[J]. Clin Exp Metastasis,1998,16: 751-756.
[9]. Taetle R,Howell SB,GiJuliani FC,et al. Comparison of the activity of doxorubicin analogues using colony-forming assays and human xenografts[J]. Cancer,1982,50: 1455-1461.
[10]. Sawada M,Terada N,Wada A,et al. Estrogen-and androgen-responsive growth of human ovarian adenocarcinoma heterotrans-planted into nude mice[J]. Int J Cancer, 1990,45:359-363.
[11].伍细丕,钱林发.实验动物与肿瘤研究[M].北京：中国医药科技出版社,2000.78.
[12].陈爱平,王和,彭芝兰,等.人卵巢癌裸鼠移植瘤和腹水瘤模型的建立及形态学观 察.肿瘤,2001,21(2)：82-84.
[13].陈爱平,高国兰,王和,等.人卵巢癌裸鼠移植腹水瘤模型的建立.实用癌症杂志,2000,15(2)：113-115.
[14].岳静,李静,刑辉,等.三种人卵巢癌动物模型的生物学特性比较.现代妇产科进展,2002,11(5)：334-336.
[15]. Turner JH, Rose AH, Glancy RJ, et al. Orthotopic xenografts of human melanoma and colonic and ovarian carcinoma in sheep to evaluate radioimmotherapy. Br J Cancer,1998,78:486-494.
[16].李静,刑辉,高庆蕾,等.人卵巢癌裸鼠原位移植瘤模型的建立及其生物学特性研究.中华妇产科杂志,2003,38(6)：376-378.
[17]Nakayama K, Takebayashi Y, Hata K,et al.Allelic loss at 19q12 and Xq11-12 predict an adverse clinical outcome in patients with mucinous ovarian tumours of low malignant potential. Br J Cancer,2004,90(6):1204-1210.
[18]Stronach EA, Sellar GC, Blenkiron C,et al. Identification of clinically relevant genes on chromosome II in a functional model of ovarian cancer tumor suppression Cancer Res,2003,63(24):8648-55.
[19]Maheshwari A, Gupta S. Is semen an etiologic factor in the development of primary peritoneal carcinoma and epithelial ovarian cancer? Med Hypotheses,2005: 64(2):264-266.
[20]Diebold J, Seemuller F, Lohrs U. K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy. Lab Invest,2003:83(2):251-258.
[21]Tammela J, Odunsi K. Gene expression and prognostic significance in ovarian cancer. Minerva Ginecol,2004:56(6):495-502.
[22]Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol,2004:22(23):4700-4710.
[23]Sanchez-Martin M. Brain tumour stem cells:implications for cancer therapy and regenerative medicine.Curr Stem Cell Res Ther,2008,3 (3):197-207.
[24]Campo-Paysaa F, Marletaz F, Laudet V, et al. Retinoic acid signaling in development:tissue-specific functions and evolutionary origins.Genesis,2008,46 (11):640-656.
[25]Lin LM, Li BX, Xiao JB, et al. Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis inhuman hepatoma, breast cancer, and lung cancer cells in vitro.World J Gastroenterol,2005,11 (36):5633-5637.
[26]Voigt A, Zintl F. Effects of retinoic acid on proliferation, apoptosis, cytotoxicity, migration, and invasion of neuroblastoma cells. Med PediatrOncol,2003,40(4): 205-213.
[27]Chiu P M, Feng H C, Benbrook D M, et al. Effect of all-trans retinoicacid on tissue dynamics of choriocarcinoma cell lines:an organotypicmodel. J Clin Pathol,2006, 59 (8):845-850.
[28]Zhang Y, Jia S, Liu Y, et al. A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl MedCommun,2007,28(4): 251-255.
[29]Kast RE. Potential for all-trans retinoic acid (tretinoin) to enhance interferon-alpha treatment response in chronic myelogenous leukemia, melanoma, myeloma and renal cell carcinoma.Cancer Biol Ther,2008,7 (10):1515-1519.
[30]Hail NJ, Lotan R. Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl) retinamide. Bio Chem, 2001,276(49):45614-45621.
[31]Elmore E, Luc TT, Steele VE, et al. Comparative tissue specific toxicities of 20 cancer p reventive agents using cultured cells from 8 different normal human ep ithelia. In Vitr Mol Toxicol,2001,14 (3):191-207.
[32]Simeone AM, Deng CX, Kelloff GJ, et al. N-(4-Hydroxyphenyl) retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carci-nogenesis,2005,26 (5):1000-1007.
[33]Zou C, Vlastos AT, Yang L, et al. Effect of 4-hydroxyphenylret namide on human cervical epithelial and cancer cell lines. J Soc Gynecol Investig,2003,10 (1):41-48.
[34]Golubkov V, Garcia A, Markland FS. Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells. Anticancer Res,2005,25 (1A):249-253.
[35]Cuello M, Coats AO, Darko I, et al. N-(4-hydroxyphenyl) retinamide (4-HPR) enhances TRAIL mediated apoptosis through enhancement of a mitochondrial dependent amplification loop in ovarian cancer cell lines. Cell Death Differ,2004,11 (5):527-541.
[36]Ohlmann CH, Jung C, Jaques G. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl) retinamide] sufficient for cancer therapy?.Int J Cancer,2002,100 (5):520-526.
[37]Zou CP, Kurie JM,Lotan D, et al. Higher potency of N-(4-hydroxyphenyl) retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res,1998,4 (5):1345-1355.
[38]Ohi Y, Kim R, Toge T1 overcoming of multidrug resistance by introducing the apoptosis gene, bc4 xs, into MRP-overexpressing drug resistant cells, Int J Oncol, 2000,16:959-9691.
[1]Hail N J r,Lotan RVlMitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydrox-yphenyl) retinamide[J].J Biol Chem,2001,276 (49):45614-45621.
[2]刘小珊.维生素甲类化合物与细胞调亡的诱导[J].重庆医科大学学报,1997,22(4)：386-389.
[3]Dipietrantonio AM,Hsieh TC ,J uan G, et al.Fenretinide-induced Caspase-3 activity involves increased protein stability in a mechanism distinct from reactive species elevation [J].Cancer Res,2000,60 (16):4331-4335.
[4]Formelli F,Clerici M,Campa T, et al. Five-year administration of fenretinide pharmacokinetics and effects on plasma retino-concentrations[J].J Clin Oncol, 1993,11 (10):2036-2042.
[5]Asumendi A,Morales MC,Alvarez A, et al.Implication of mito-chondria derived ROS and cardioliplin peroxindation in N-(4-hy-droxyphenyl) retinamide-induced apoptosis [J]. B r J Cancer,2002,86(12):1951-1956.
[6]Mariotti A,Marcora E,Bunone G, et al. N-(4-Hydroxyphenyl) retinamide:a potent inducer of apoptosis in human neuroblastomacells[J].J Natl Cancer Inst,1994,86 (16):1245-1247.
[7]De Palo G,Veronesi U,Camerini T, et al.Can fenretinide protect women against ovarian cancer[J].J Natl Cancer Inst,1995,87 (2):146-147.
[8]Oridate N,Lotan D,Mitchell MF, et al. Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids:implications for chemoprevention [J].J Cell Biochem,1995,23 (Suppl):S80-S86.
[9]Sheikh MS,Shao ZM,Li XS, et al. N-(4-hydroxyphenyl) retinamide (4-HPR)-mediated biological actions involve retinoid re-captor-independent pathways in human breast carcinoma [J].Carci nogenesis,1995,16 (10):2477-2486.
[10]Kalemkerian GP,Slusher R,Ramalingam S, et al.Growth inhibition and induction of apoptosis by fenretinide in small-cell lungcancer cell lines [J].J Natl Cancer Inst, 1995,87 (22):1674-1680.
[11]Supino R,Crosti M,Clerici M, et al.Induction of apoptosis by fenretinide (4-HPR) in human overian carcinoma cells and its association with retinoic acid receptor expression[J].Int J Cancer,1996,65 (4):491-497.
[12]Oridate N, Lotan D,Xu XC, et al.Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl) reti-namide in human head and neck squamous cell carcinoma cell lines[J]. Clin Cancer Res,1996,2 (5):855-863.
[13]Sun SY, Li W, Yue P, et al.Midiation of N-(4-hydroxyphenyl) Retinamide-induced apoptosis in human cancer cells by different mechanisms[J].Cancer Res,1999,59 (10):2493-2498.
[14]彭黎明,王曾礼.细胞凋亡的信号传导[A].细胞凋亡的基础与临床[M].第8版.北京：人民卫生出版社,2000.64-65.
[15]Bruno S,Tenca C,Saverino D, et al.Apoptosis of squamous cells at different stage of cacinogenesis following 4-HPR treatment[J]. Carci nogenesis,2002,23 (3):447-456.
[16]Shen JC,Wang TT,Chang S, et al.Mechanistic studies of the effects of the retinoid N-(4-hydroxyphenyl) retinamide on prostate cancer cell growth and apoptosis [J].Mol Carci nog,1999,24 (3):160-168.
[17]Suzuki S,Higuchi M,Proske RJ, et al.Implication of mitochon-Dria-derived reactive oxygen species,cytochrome C and Caspase-3 in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells [J]. Oncongen,1999,18 (46):6380-6387.
[18]You KR,Wen J,Lee ST, et al.Cytochrome C oxidase subunit Ⅲ:a molecular marker for N-(4-hydroxyphenyl) retinamide-induced oxidative stress in hepatoma cells[J].J Boil Chem,2002,277 (6):3870-3877.
[19]Hail NJ r,Lotan R.Mitochondrial permeability transition is a central coordinating event in N2(42hydroxyphenyl) retinamide-induced apoptosis [J]. Cancer Epi demiol Biomarkers Prev,2000,9 (12):1293-1301.
[20]O'Donnell PH,Guo WX,Reynolds CP, et al.N-(4-hydroxyphe-nyl) retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines,but not to non-malignant lymphocytes[J].Leukemia,2002,16 (5):902-910.
[21]Maurer BJ,Metelitsa LS,Seeger RC, et al.Increase of ceramideand induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines[J].J Natl Cancer Inst,1999,91 (13):1138-1146.
[22]Maurer BJ,Melton L,Billups C, et al.Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl) retinamide and modulators of ceramide metabolism[J].J Natl Cancer Inst,2000,92 (23):1897-1909.
[23]Wang H,Maurer BJ,Reynolds CP, et al. N-(4-hydroxyphenyl) retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase[J]. Cancer Res,2001,61 (13):5102-5105.
[24]Puduvalli VK,Saito Y,Xu R, et al.Fenretinide activates Caspases and induces apoptosis in gliomas[J]. Cli n Cancer Res,1999,5 (8):2230-2235.
[25]You KR,Shin MN,Park RK, et al.Activation of Caspase-8 during N-(4-hydroxyphenyl) retinamide-induced apoptosis in fasdefective hepatoma cells [J]. Hepatology,200134 (6):1119-1127.
[26]Giuntoli RL,Rodriguez GC, Whitaker RS, et al. Mucin gene expression in ovarian cancer. Cancer Res 1998,58:5546-5550.
[27]Suresh G, Stan L, Michael A, et al. Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma.[J] J Natl Cancer Inst,2001,93(7):516-525.
[28]Fanjul AN,Delia D,Pierotti MA, et al. N-4-hydroxyphenyl retinamide is a highly selective activator of retinoid receptors[J].J Biol Chem,1996,271 (37):22441 22446.
[29]Camerini T,Mariani L,de Palo G, et al.Safety of the synthetic retinoid fenretinide long-term results from a controlled clinical trial for the prevention of contralateral breast cancer [J] J Cli nOncol,2001,19 (6):1664-1670.
[30]Piedrafita FJ,Pfahl M.Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require Caspase activation[J]. Mol Cell Biol,1997,17(11):6348-6358.
[31]MM SJ,Lee SY, Kim EJ, et al.Antiproliferative mechanism of retinoid derivatives in ovarian cancer cells [J]. Cancer Lett,2001,174 (2):127-134.
[32]Lovat PE,Ranalli M,Annichiarrico2Petruzzelli M, et al. Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma[J]. Exp Cell Res,2000,260 (1):50-60.
[33]Hursting SD,Shen JC,Sun XY, et al.Modulation of cyclophilin gene expression by N2(4-hydroxyphenyl) retinamide:association with reactive oxygen species generation and apoptosis [J]. Mol Carcinog,2002,33 (1):16-24.
[34]Yang X, Hao Y,Ding Z, et al.BAG-1 promotes apoptosis induced by N-(4-hydroxyphenyl) retinamide in human cervical carcinoma cells [J].Exp Cell Res,2000,256 (6):491-499.
[35]Chen YR,Zhou G, Tan TH.C-J un N-terminal kinase mediates apoptotic signaling induced by N-(4-hydroxyphenyl) retinamide [J]. Mol Pharmacol,1999,56 (6):1271-1279.
[36]Brenner B, Koppenhoefer U, Weinstock C, et al.Fas- or Ce Ramide-induced apoptosis is mediated by a Racl-regulated activetion of J un N-terminal kinase/p38 kinases and GADD153 [J].JBiol Chem,1997,272 (35):22173-22181.
[37]Panigone S,Bergomas R, Fontanella E, et al.Up-regulation of prosaposin by the retinoid HPR and its effect on ceramide production and integrin receptors [J]. FAS EB J,2001,15 (8):1475-1477.
[1]Liu J, Matulonis UA. New advances in ovarian cancer[J].Oncology,2010,24(8): 721-728.
[2]Bristow RE, Tomaoruz RS, Armstrong DK, et al. Survival effect of maximal eytoreduetive surgery for advanced ovadan carcinoma during the platinum era: ameta-analysis[J]. J Clin Oncol,2002,20(5):1248-1259.
[3]Frei E. Clinical cancer research:anem battled species. Cancer 1982.50:1979.
[4]Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer:primary and interval cytoreductive surgery [J]. Semin Oncol,1998,25(3): 326-334.
[5]Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer:a meta analysis[J]. Gynecol Oncol,2006, 103(3):1070-1076.
[6]梅琳琳.晚期卵巢癌的NACT[J].国外医学·计划生育生殖健康分册,2006,25(6)：336.
[7]Le T, Alshaikh G, Hopkins L, et al. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking[J]. Ann Surg Oncol,2006,13(12):1711-1716.
[8]Le T, Faught W, Hopkins L, et al. Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer[J]. Int J Gynecol Cancer,2005,15(5):770-775.
[9]Schwartz PE, Rutherford TJ, OIaIT s, et al. Neoadjuvant chemotherapyfor advanced ovarian callcer:long-term survival. Gynecol Oncol,1999,72:93-99.
[10]Vergote I, DeWever I, TiaM-TW, et al. Neoadjuvant chemotherapy or primary debulking surgeryin advanced ovarian carcinoma:a retrospective arIalys of 285 patients. Gynecul Oneol,1998,71:431-436.
[11]Angioli R, Palaia I, Inllo MA. Diagnostic open laparoscopy in the management of advanced ovarian cancer, Gynecol Oncol.2006,100 (3):455-461
[12]Deffieux X, Castaignc D, Pomel C. Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. lnt J Gynecol Cancer 2006,16(s1):35-40.
[13]Vergote 1, De Wever 1, Deeloedt J, et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian carcinoma. Semin Oncol,2000,27[Suppl]: 31-36.
[14]Fagotti A, Fanfani F, Ludovisi M, et al. Role of laparoscopy to assess the change of optimal cytoreductive surgery in advanced ovarian cancer:a pilot study. GynecoI Onenl.2005.96(3):729.735.
[15]Bristow RE, Duska LR, Lambrou NC. et al, A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomagraphy. Cancer, 2000,89(7):1532-1540.
[16]Vergote I, Marquette S, Amant F, el al. Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma. Int J Gynecol Cancer, 2005,15(5):776-779.
[17]Abu-Rustum NR, Sonoda Y, Chi DS, et al. The efect of C02 Pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer. Gynecol Oncol,2003, 90(2):431-434.
[18]Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer:a meta analysis[J]. Gynecol Oncol,2006, 103(3):1070-1076.
[19]Loizzi V, Cormio G, Resta L, et al. Neoadjuvant chemotherapy in advanced ovarian cancer:a case-control study [J].Int J Gynecol Cancer,2005,15(2):217-223.
[20]Everett EN, French AE, Stone RL, et al. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer [J]. Am J Obstet Gynecol,2006,195 (2):568-574.
[21]Shimizu Y. Recent advances in inrtaarterial chemotherapy in gymecologic malignancy. Gan To Kagaku Ryoho,2002,29(2):189-196
[22]Hegazy MA, Hegazi RA, Elshafei MA, et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World J Surg Oncol,2005,3(1): 57-64
[23]Loizzi V, Cormio G, Resta L, et al. Neoadjuvant chemotherapy in advanced ovarian cancer:a case, control study, Int J Gynecol Cancer.2005,15(2):217-223
[24]Lee SJ, Kim BG, Lee JW, et al. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynecol Res,2006.32(1): 90-106
[25]Giannopoulos T, Butler-Manuel S. Taylor A. et al. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma. Ear J Gynaecol Oncol,2006,27(1):25-28
[26]Kayikeiolglu F, Kose MF, Boran N, et al. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer,2001,11: 466-470.
[27]Kllhn W, ltmkeS, Spillhe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs surival for patients with poor prognosis in lnternation Federnation of Gynecolog and Obsterics Ⅲc ovarian careinoma. Cancer.2001.92:2585-2591.
[28]Bruchim I, Altaras M, fisherman A. Age contrasts in clinical characteristics and pattern of care in patients wi th epithelial ovarian cancer. Gynecol Oncol,2002.86(3): 274-279
[29]Ushijima K, Ora S, Komai K, et al. Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. Int Surg, 2002,87(3):185-90.
[30]Woodward Pi, Hosseinzadeh K, Saenger JS. From the archiyes of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation. Radiographics, 2004,24(1):225-246.
[31]Obeidat B, LatimerJ. Can optimal primary cytoreduction be predicted in advanced stage epitllelial ovarian cancer? Role of preoperative serum CA125 level. Gynecol Obstet Invest,2004,57(3):153-156.
[32]Trope C, Paulsen T, Baekelandt M, et al. Controversies in surgicaltre treatment of advanced ovarian cancer. Tidsskr Nor Laegeforen,2000,120(7):824-830
[33]Hatae M, Onishi Y, Nakamura T, et al. Neoadjuvant chemotherapy for advaneed epithelial ovarian cancel. Gan To magaku Ryoho,2001,28(12):1833-1837.
[34]Vergote I. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovariall cancel. Int J Gynecol Cancer,2003,3[Supple 1]:118.
[35]Bruchim I, Altaras M, fisherman A. Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecol Oncol,2002,86(3): 274-279
[1]SchilderR, BradyMF, SpriggsD, et al. Pilot Evaluation of high-dose carbo platin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer:A Gynecologic Oncology Group Study. Gynecol Oncol.2003,88(1):3-8.
[2]李洪君,刘丽影.复发性卵巢癌的诊治现状[J].临床肿瘤学杂志.2010,12(07)：122-124.
[3]叶大风,谢幸.上皮性卵巢癌的一线化疗[J].实用妇产科杂志.2010,7(03)：：98-100.
[4]ChanYM, NgTY, HextanYS, et al. Quality of life in women treated with neoadjuvantchemo therapy for advanced ovarian cancer:A prospective long itudina lstudy. Anticancer Res.2008,11 (3):247-254.
[5]陈建国,郑伟,李爱玲.顺铂不同途径给药在卵巢癌化疗中的作用[J].癌症.2003,12(03)：24-25.
[6]周林平,罗文莉.多帕菲、卡铂联合腹腔置管治疗卵巢癌的临床观察[J].临床和实验医学杂志.2007,5(12)：89-90.
[7]吴溪.卵巢癌的化疗[J].实用妇科与产科杂志.2010,8(12)：14-16.
[8]梁凌毅.复发性卵巢癌化疗失败后有效的姑息放疗[J].国外医学.妇产科学分册.2005,6(12)：234-236.
[9]张超,崔恒,钱和年.卵巢癌化疗药物的新进展[J].中国妇产科临床杂志.2001,2(4)：245-248.
[10]王旭辉,高春英.紫杉醇联合卡铂治疗复发性上皮性卵巢癌48例临床观察[J].中国妇幼保健.2009,2(14)：56-59.
[11]张桂萍.卵巢癌化疗的进展(综述)[J].中国城乡企业卫生.2009,4(02)：78-80.
[12]杨国宏,张际绯.卵巢癌化疗的研究进展[J].牡丹江医学院学报.2010,7(02)：45-47.
[13]易晓芳,丰有吉.复发性卵巢癌的化疗进展[J].肿瘤学杂志.2008,11(02)：10-12.
[14]赵静,薛圣留,冯泽蛟.卵巢癌腹腔化疗的研究进展[J].中国实用妇科与产科杂志. 2007,23(04)：311-314.
[15]AgostinoG, AmantF, BertelootP, et al. Phase II study of gemc-itabineinre current platinum-and paclitaxel-resistant ovarian cancer. Carcinogenesis.2010,23(4):23-28.
[16]CopelandL, BookmanM,TrimbleE,etal. Clinical trials of newer regimens for treating ovarian cancer:the rationale for Gynecologic Oncology Group Protocol GOG182-ICON5. Gynecologic Oncology.2003,90(2):1-7.
[17]CantuMG, BudaA, ParmaG, et al.Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first line platinum-based regimens. J Clin Oncol. 2002,12(12):1232-1237.
[18]ChiaraS, TognoniA, Pastronel, et al. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer. Gynecologic Oncology.2004,93 (2):474-478.
[19]李贤,李斌,吴令英.脂质体阿霉素在卵巢癌二线化疗中的应用[J].国外医学.妇产科学分册.2008,14(03)：567-569.
[20]徐华瑞.联合化疗对晚期卵巢癌的疗效评价[J].中国医药导报.2008,5(26)：361-364.
[2].糜若然,瞿全新主编.妇科肿瘤基因诊断与治疗.北京：人民卫生出版社,2001.304-305.
[3]. Hermiston T. Gene delivery from replication-selective viruses:aiming guided missiles in the war against cancer. J Clin Invest,2000,105(9):1169-1172.
[4]. Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer:primary and interval cytoreductive surgery [J]. Semin Oncol,1998,25(3): 326-334.
[5]. Mondimore FM, Fuller GA, DePaulo JR, Jr. Drug combinations for mania. J Clin Psychiatry.2003;64 Suppl 5:25-31.
[6]. Curatolo M, Sveticic G. Drug combinations in pain treatment:a review of the published evidence and a method for finding the optimal combination. Best Pract Res Clin Anaesthesiol.2002 Dec;16(4):507-519.
[7]. Kim KK, Lange TS, Singh RK,et al. Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide,5-fluorouracil and mitomycin C. BMC Cancer.2012,13(12):147-151.
[8]. Braga PC, Ricci D, Dal Sasso M. Daptomycin morphostructural damage in Bacillus cereus visualized by atomic force microscopy J Chemother.2002 Aug;14(4):336-341.
[9]. Paul TR, Venter A, Blaszczak LC, Parr TR, Jr., Labischinski H, Beveridge TJ. Localization of penicillin-binding proteins to the splitting system of Staphylococcus aureus septa by using a mercury-penicillin V derivative. J Bacteriol.1995 Jul;177(13):3631-3640
[10]. Illuzzi G, Bernacchioni C, Aureli M, et,al. Sphingosine kinase mediates resistance to the synthetic retinoid N-(4-hydroxyphenyl)retinamide in human ovarian cancer cells. J Biol Chem.2010,285(24):18594-602.
[11]. Rokoss MJ, Teo KK. Ramipril in the treatment of vascular diseases. Expert Opin Pharmacother.2005 Sep;6(11):1911-1919.
[12]. Sanchez-Martin M. Brain tumour stem cells:implications for cancer therapy and regenerative medicine.Curr Stem Cell Res Ther,2008,3(3):197-207.
[13]. Campo-Paysaa F, Marletaz F, Laudet V, et al. Retinoic acid signaling in development:tissue-specific functions and evolutionary origins.Genesis,2008,46 (11):640-656.
[14]. Lin LM, Li BX, Xiao JB, et al. Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis inhuman hepatoma, breast cancer, and lung cancer cells in vitro.World J Gastroenterol,2005,11 (36):5633-5637.
[15].Voigt A, Zintl F. Effects of retinoic acid on proliferation, apoptosis, cytotoxicity, migration, and invasion of neuroblastoma cells. Med PediatrOncol,2003,40(4) 205-213.
[16]. Zhang Y, Jia S, Liu Y, et al. A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl MedCommun,2007,28(4): 251-255.
[17]. Kast R E. Potential for all-trans retinoic acid (tretinoin) to enhance interferon-alpha treatment response in chronic myelogenous leukemia, melanoma, myeloma and renal cell carcinoma.Cancer Biol Ther,2008,7 (10):1515-1519.
[18]. Hail NJ,Lotan R. Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl) retinamide. Bio Chem, 2001,276(49):45 614-45621.
[19]. Elmore E, Luc TT, Steele VE, et al. Comparative tissue specific toxicities of 20 cancer p reventive agents using cultured cells from 8 different normal human epithelia. In V itrM ol Toxicol,2001,14 (3):191-207.
[20]. Eyou WANG, Jun Li, Guohm YANG, et al. Impact of 4HPR on the expression of E-Cad in human bladder transitional epithelial cancer cells T24[J]. Huazhong Univ Sci Tcchnol[Med Sci],2012,32(2):237-241.
[21]. Hail NJ, Lotan R. Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl)retinamide[J]. Bio Chem. 2001276(49):45614-21.
[22]. Valsecchi M, Aureli M, Mauri L, et al. Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids. J Lipid Res. 2010,51(7):1832-40..
[23]. Golubkov V, Garcia A, Markland FS. Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells. Anticancer Res,2005,25 (1A):249-253.
[24]. Cuello M, Coats AO, Darko I, et al. N-(4-hydroxyphenyl) retinamide (4-HPR) enhances TRAIL mediated apoptosis through enhancement of a mitochondrial dependent amplification loop in ovarian cancer cell lines. Cell Death Differ,2004,11 (5):527-541.
[25]. Ohlmann CH, Jung C, Jaques G. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-4-hydroxyphenyl) retinamide] sufficient for cancer therapy?.Int J Cancer,2002,100 (5):520-526.
[26]. Zou CP, Kurie JM, Lotan D, et al. Higher potency of N-(4-hydroxy-phenyl) retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res,1998,4 (5):1345-1355.
[27]. Pasctto LM, D'Andrea MR,Brandes AA, et al.The development of platinum compounds and their possible combination[J].Crit Rev Oncol Hematol.2006,60(1): 59-75.
[28]. Shimada K, Nakamura M, Isida, et al. Requirement of c-jun for testosterone-induced sensitization to N-(4-hydroxyphenyl)retinamide-induced apoptosis[J]. Mol Carcinog. 2003,36(3):115-22.
[29]. Chou TC.Theoretical basis, experimental design,and computedzexl simulation of synergism and antagonism in drug combination studies [J].Pharmacol Rev.2006, 58(3):621-681
[30]. Edinger AL, Thompson CB. Death by design:apoptosis, necrosis and autophagy[J]. Curr Opin Cell Biol.2004,16(6):663-669.
[1]. Jemal A,Siegel R,Ward E, et al. Cancer statistics[J]. CA Cancer J Clin,2006,56: 106-130.
[2]. Crawford R. Gynecologic oncology:current diagnosis and treatment. The New England Journal of Medicine,1996,25:203.
[3]. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer:a meta analysis [J]. Gynecol Oncol,2006, 103(3):1070-1076.
[4]. Daniel GR,Yang G,Liu GZ, et al. Ovarian cancer:pathology,biology,and disease models[J]. Front Biosci,2010,14:2089-2102.
[5]. Markman M. Management of oVarian cancer. An impressive history,of improvemention suvivial and quality of life[J]. Oncology(Williston Park),2006,20(4): 347-354
[6].吴令英.卵巢恶性肿瘤治疗进展[J].中国临床肿瘤学教育,2007：437-439。
[7]. Fu X, Hofman RM. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens [J]. Anticancer Res,1993,13:283-286.
[8]. Kiguchi K,Kubota T,Aoki D,et al. A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer[J]. Clin Exp Metastasis,1998,16: 751-756.
[9]. Taetle R,Howell SB,GiJuliani FC,et al. Comparison of the activity of doxorubicin analogues using colony-forming assays and human xenografts[J]. Cancer,1982,50: 1455-1461.
[10]. Sawada M,Terada N,Wada A,et al. Estrogen-and androgen-responsive growth of human ovarian adenocarcinoma heterotrans-planted into nude mice[J]. Int J Cancer, 1990,45:359-363.
[11].伍细丕,钱林发.实验动物与肿瘤研究[M].北京：中国医药科技出版社,2000.78.
[12].陈爱平,王和,彭芝兰,等.人卵巢癌裸鼠移植瘤和腹水瘤模型的建立及形态学观 察.肿瘤,2001,21(2)：82-84.
[13].陈爱平,高国兰,王和,等.人卵巢癌裸鼠移植腹水瘤模型的建立.实用癌症杂志,2000,15(2)：113-115.
[14].岳静,李静,刑辉,等.三种人卵巢癌动物模型的生物学特性比较.现代妇产科进展,2002,11(5)：334-336.
[15]. Turner JH, Rose AH, Glancy RJ, et al. Orthotopic xenografts of human melanoma and colonic and ovarian carcinoma in sheep to evaluate radioimmotherapy. Br J Cancer,1998,78:486-494.
[16].李静,刑辉,高庆蕾,等.人卵巢癌裸鼠原位移植瘤模型的建立及其生物学特性研究.中华妇产科杂志,2003,38(6)：376-378.
[17]Nakayama K, Takebayashi Y, Hata K,et al.Allelic loss at 19q12 and Xq11-12 predict an adverse clinical outcome in patients with mucinous ovarian tumours of low malignant potential. Br J Cancer,2004,90(6):1204-1210.
[18]Stronach EA, Sellar GC, Blenkiron C,et al. Identification of clinically relevant genes on chromosome II in a functional model of ovarian cancer tumor suppression Cancer Res,2003,63(24):8648-55.
[19]Maheshwari A, Gupta S. Is semen an etiologic factor in the development of primary peritoneal carcinoma and epithelial ovarian cancer? Med Hypotheses,2005: 64(2):264-266.
[20]Diebold J, Seemuller F, Lohrs U. K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy. Lab Invest,2003:83(2):251-258.
[21]Tammela J, Odunsi K. Gene expression and prognostic significance in ovarian cancer. Minerva Ginecol,2004:56(6):495-502.
[22]Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol,2004:22(23):4700-4710.
[23]Sanchez-Martin M. Brain tumour stem cells:implications for cancer therapy and regenerative medicine.Curr Stem Cell Res Ther,2008,3 (3):197-207.
[24]Campo-Paysaa F, Marletaz F, Laudet V, et al. Retinoic acid signaling in development:tissue-specific functions and evolutionary origins.Genesis,2008,46 (11):640-656.
[25]Lin LM, Li BX, Xiao JB, et al. Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis inhuman hepatoma, breast cancer, and lung cancer cells in vitro.World J Gastroenterol,2005,11 (36):5633-5637.
[26]Voigt A, Zintl F. Effects of retinoic acid on proliferation, apoptosis, cytotoxicity, migration, and invasion of neuroblastoma cells. Med PediatrOncol,2003,40(4): 205-213.
[27]Chiu P M, Feng H C, Benbrook D M, et al. Effect of all-trans retinoicacid on tissue dynamics of choriocarcinoma cell lines:an organotypicmodel. J Clin Pathol,2006, 59 (8):845-850.
[28]Zhang Y, Jia S, Liu Y, et al. A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl MedCommun,2007,28(4): 251-255.
[29]Kast RE. Potential for all-trans retinoic acid (tretinoin) to enhance interferon-alpha treatment response in chronic myelogenous leukemia, melanoma, myeloma and renal cell carcinoma.Cancer Biol Ther,2008,7 (10):1515-1519.
[30]Hail NJ, Lotan R. Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl) retinamide. Bio Chem, 2001,276(49):45614-45621.
[31]Elmore E, Luc TT, Steele VE, et al. Comparative tissue specific toxicities of 20 cancer p reventive agents using cultured cells from 8 different normal human ep ithelia. In Vitr Mol Toxicol,2001,14 (3):191-207.
[32]Simeone AM, Deng CX, Kelloff GJ, et al. N-(4-Hydroxyphenyl) retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carci-nogenesis,2005,26 (5):1000-1007.
[33]Zou C, Vlastos AT, Yang L, et al. Effect of 4-hydroxyphenylret namide on human cervical epithelial and cancer cell lines. J Soc Gynecol Investig,2003,10 (1):41-48.
[34]Golubkov V, Garcia A, Markland FS. Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells. Anticancer Res,2005,25 (1A):249-253.
[35]Cuello M, Coats AO, Darko I, et al. N-(4-hydroxyphenyl) retinamide (4-HPR) enhances TRAIL mediated apoptosis through enhancement of a mitochondrial dependent amplification loop in ovarian cancer cell lines. Cell Death Differ,2004,11 (5):527-541.
[36]Ohlmann CH, Jung C, Jaques G. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl) retinamide] sufficient for cancer therapy?.Int J Cancer,2002,100 (5):520-526.
[37]Zou CP, Kurie JM,Lotan D, et al. Higher potency of N-(4-hydroxyphenyl) retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res,1998,4 (5):1345-1355.
[38]Ohi Y, Kim R, Toge T1 overcoming of multidrug resistance by introducing the apoptosis gene, bc4 xs, into MRP-overexpressing drug resistant cells, Int J Oncol, 2000,16:959-9691.
[1]Hail N J r,Lotan RVlMitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydrox-yphenyl) retinamide[J].J Biol Chem,2001,276 (49):45614-45621.
[2]刘小珊.维生素甲类化合物与细胞调亡的诱导[J].重庆医科大学学报,1997,22(4)：386-389.
[3]Dipietrantonio AM,Hsieh TC ,J uan G, et al.Fenretinide-induced Caspase-3 activity involves increased protein stability in a mechanism distinct from reactive species elevation [J].Cancer Res,2000,60 (16):4331-4335.
[4]Formelli F,Clerici M,Campa T, et al. Five-year administration of fenretinide pharmacokinetics and effects on plasma retino-concentrations[J].J Clin Oncol, 1993,11 (10):2036-2042.
[5]Asumendi A,Morales MC,Alvarez A, et al.Implication of mito-chondria derived ROS and cardioliplin peroxindation in N-(4-hy-droxyphenyl) retinamide-induced apoptosis [J]. B r J Cancer,2002,86(12):1951-1956.
[6]Mariotti A,Marcora E,Bunone G, et al. N-(4-Hydroxyphenyl) retinamide:a potent inducer of apoptosis in human neuroblastomacells[J].J Natl Cancer Inst,1994,86 (16):1245-1247.
[7]De Palo G,Veronesi U,Camerini T, et al.Can fenretinide protect women against ovarian cancer[J].J Natl Cancer Inst,1995,87 (2):146-147.
[8]Oridate N,Lotan D,Mitchell MF, et al. Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids:implications for chemoprevention [J].J Cell Biochem,1995,23 (Suppl):S80-S86.
[9]Sheikh MS,Shao ZM,Li XS, et al. N-(4-hydroxyphenyl) retinamide (4-HPR)-mediated biological actions involve retinoid re-captor-independent pathways in human breast carcinoma [J].Carci nogenesis,1995,16 (10):2477-2486.
[10]Kalemkerian GP,Slusher R,Ramalingam S, et al.Growth inhibition and induction of apoptosis by fenretinide in small-cell lungcancer cell lines [J].J Natl Cancer Inst, 1995,87 (22):1674-1680.
[11]Supino R,Crosti M,Clerici M, et al.Induction of apoptosis by fenretinide (4-HPR) in human overian carcinoma cells and its association with retinoic acid receptor expression[J].Int J Cancer,1996,65 (4):491-497.
[12]Oridate N, Lotan D,Xu XC, et al.Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl) reti-namide in human head and neck squamous cell carcinoma cell lines[J]. Clin Cancer Res,1996,2 (5):855-863.
[13]Sun SY, Li W, Yue P, et al.Midiation of N-(4-hydroxyphenyl) Retinamide-induced apoptosis in human cancer cells by different mechanisms[J].Cancer Res,1999,59 (10):2493-2498.
[14]彭黎明,王曾礼.细胞凋亡的信号传导[A].细胞凋亡的基础与临床[M].第8版.北京：人民卫生出版社,2000.64-65.
[15]Bruno S,Tenca C,Saverino D, et al.Apoptosis of squamous cells at different stage of cacinogenesis following 4-HPR treatment[J]. Carci nogenesis,2002,23 (3):447-456.
[16]Shen JC,Wang TT,Chang S, et al.Mechanistic studies of the effects of the retinoid N-(4-hydroxyphenyl) retinamide on prostate cancer cell growth and apoptosis [J].Mol Carci nog,1999,24 (3):160-168.
[17]Suzuki S,Higuchi M,Proske RJ, et al.Implication of mitochon-Dria-derived reactive oxygen species,cytochrome C and Caspase-3 in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells [J]. Oncongen,1999,18 (46):6380-6387.
[18]You KR,Wen J,Lee ST, et al.Cytochrome C oxidase subunit Ⅲ:a molecular marker for N-(4-hydroxyphenyl) retinamide-induced oxidative stress in hepatoma cells[J].J Boil Chem,2002,277 (6):3870-3877.
[19]Hail NJ r,Lotan R.Mitochondrial permeability transition is a central coordinating event in N2(42hydroxyphenyl) retinamide-induced apoptosis [J]. Cancer Epi demiol Biomarkers Prev,2000,9 (12):1293-1301.
[20]O'Donnell PH,Guo WX,Reynolds CP, et al.N-(4-hydroxyphe-nyl) retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines,but not to non-malignant lymphocytes[J].Leukemia,2002,16 (5):902-910.
[21]Maurer BJ,Metelitsa LS,Seeger RC, et al.Increase of ceramideand induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines[J].J Natl Cancer Inst,1999,91 (13):1138-1146.
[22]Maurer BJ,Melton L,Billups C, et al.Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl) retinamide and modulators of ceramide metabolism[J].J Natl Cancer Inst,2000,92 (23):1897-1909.
[23]Wang H,Maurer BJ,Reynolds CP, et al. N-(4-hydroxyphenyl) retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase[J]. Cancer Res,2001,61 (13):5102-5105.
[24]Puduvalli VK,Saito Y,Xu R, et al.Fenretinide activates Caspases and induces apoptosis in gliomas[J]. Cli n Cancer Res,1999,5 (8):2230-2235.
[25]You KR,Shin MN,Park RK, et al.Activation of Caspase-8 during N-(4-hydroxyphenyl) retinamide-induced apoptosis in fasdefective hepatoma cells [J]. Hepatology,200134 (6):1119-1127.
[26]Giuntoli RL,Rodriguez GC, Whitaker RS, et al. Mucin gene expression in ovarian cancer. Cancer Res 1998,58:5546-5550.
[27]Suresh G, Stan L, Michael A, et al. Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma.[J] J Natl Cancer Inst,2001,93(7):516-525.
[28]Fanjul AN,Delia D,Pierotti MA, et al. N-4-hydroxyphenyl retinamide is a highly selective activator of retinoid receptors[J].J Biol Chem,1996,271 (37):22441 22446.
[29]Camerini T,Mariani L,de Palo G, et al.Safety of the synthetic retinoid fenretinide long-term results from a controlled clinical trial for the prevention of contralateral breast cancer [J] J Cli nOncol,2001,19 (6):1664-1670.
[30]Piedrafita FJ,Pfahl M.Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require Caspase activation[J]. Mol Cell Biol,1997,17(11):6348-6358.
[31]MM SJ,Lee SY, Kim EJ, et al.Antiproliferative mechanism of retinoid derivatives in ovarian cancer cells [J]. Cancer Lett,2001,174 (2):127-134.
[32]Lovat PE,Ranalli M,Annichiarrico2Petruzzelli M, et al. Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma[J]. Exp Cell Res,2000,260 (1):50-60.
[33]Hursting SD,Shen JC,Sun XY, et al.Modulation of cyclophilin gene expression by N2(4-hydroxyphenyl) retinamide:association with reactive oxygen species generation and apoptosis [J]. Mol Carcinog,2002,33 (1):16-24.
[34]Yang X, Hao Y,Ding Z, et al.BAG-1 promotes apoptosis induced by N-(4-hydroxyphenyl) retinamide in human cervical carcinoma cells [J].Exp Cell Res,2000,256 (6):491-499.
[35]Chen YR,Zhou G, Tan TH.C-J un N-terminal kinase mediates apoptotic signaling induced by N-(4-hydroxyphenyl) retinamide [J]. Mol Pharmacol,1999,56 (6):1271-1279.
[36]Brenner B, Koppenhoefer U, Weinstock C, et al.Fas- or Ce Ramide-induced apoptosis is mediated by a Racl-regulated activetion of J un N-terminal kinase/p38 kinases and GADD153 [J].JBiol Chem,1997,272 (35):22173-22181.
[37]Panigone S,Bergomas R, Fontanella E, et al.Up-regulation of prosaposin by the retinoid HPR and its effect on ceramide production and integrin receptors [J]. FAS EB J,2001,15 (8):1475-1477.
[1]Liu J, Matulonis UA. New advances in ovarian cancer[J].Oncology,2010,24(8): 721-728.
[2]Bristow RE, Tomaoruz RS, Armstrong DK, et al. Survival effect of maximal eytoreduetive surgery for advanced ovadan carcinoma during the platinum era: ameta-analysis[J]. J Clin Oncol,2002,20(5):1248-1259.
[3]Frei E. Clinical cancer research:anem battled species. Cancer 1982.50:1979.
[4]Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer:primary and interval cytoreductive surgery [J]. Semin Oncol,1998,25(3): 326-334.
[5]Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer:a meta analysis[J]. Gynecol Oncol,2006, 103(3):1070-1076.
[6]梅琳琳.晚期卵巢癌的NACT[J].国外医学·计划生育生殖健康分册,2006,25(6)：336.
[7]Le T, Alshaikh G, Hopkins L, et al. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking[J]. Ann Surg Oncol,2006,13(12):1711-1716.
[8]Le T, Faught W, Hopkins L, et al. Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer[J]. Int J Gynecol Cancer,2005,15(5):770-775.
[9]Schwartz PE, Rutherford TJ, OIaIT s, et al. Neoadjuvant chemotherapyfor advanced ovarian callcer:long-term survival. Gynecol Oncol,1999,72:93-99.
[10]Vergote I, DeWever I, TiaM-TW, et al. Neoadjuvant chemotherapy or primary debulking surgeryin advanced ovarian carcinoma:a retrospective arIalys of 285 patients. Gynecul Oneol,1998,71:431-436.
[11]Angioli R, Palaia I, Inllo MA. Diagnostic open laparoscopy in the management of advanced ovarian cancer, Gynecol Oncol.2006,100 (3):455-461
[12]Deffieux X, Castaignc D, Pomel C. Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. lnt J Gynecol Cancer 2006,16(s1):35-40.
[13]Vergote 1, De Wever 1, Deeloedt J, et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian carcinoma. Semin Oncol,2000,27[Suppl]: 31-36.
[14]Fagotti A, Fanfani F, Ludovisi M, et al. Role of laparoscopy to assess the change of optimal cytoreductive surgery in advanced ovarian cancer:a pilot study. GynecoI Onenl.2005.96(3):729.735.
[15]Bristow RE, Duska LR, Lambrou NC. et al, A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomagraphy. Cancer, 2000,89(7):1532-1540.
[16]Vergote I, Marquette S, Amant F, el al. Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma. Int J Gynecol Cancer, 2005,15(5):776-779.
[17]Abu-Rustum NR, Sonoda Y, Chi DS, et al. The efect of C02 Pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer. Gynecol Oncol,2003, 90(2):431-434.
[18]Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer:a meta analysis[J]. Gynecol Oncol,2006, 103(3):1070-1076.
[19]Loizzi V, Cormio G, Resta L, et al. Neoadjuvant chemotherapy in advanced ovarian cancer:a case-control study [J].Int J Gynecol Cancer,2005,15(2):217-223.
[20]Everett EN, French AE, Stone RL, et al. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer [J]. Am J Obstet Gynecol,2006,195 (2):568-574.
[21]Shimizu Y. Recent advances in inrtaarterial chemotherapy in gymecologic malignancy. Gan To Kagaku Ryoho,2002,29(2):189-196
[22]Hegazy MA, Hegazi RA, Elshafei MA, et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World J Surg Oncol,2005,3(1): 57-64
[23]Loizzi V, Cormio G, Resta L, et al. Neoadjuvant chemotherapy in advanced ovarian cancer:a case, control study, Int J Gynecol Cancer.2005,15(2):217-223
[24]Lee SJ, Kim BG, Lee JW, et al. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynecol Res,2006.32(1): 90-106
[25]Giannopoulos T, Butler-Manuel S. Taylor A. et al. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma. Ear J Gynaecol Oncol,2006,27(1):25-28
[26]Kayikeiolglu F, Kose MF, Boran N, et al. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer,2001,11: 466-470.
[27]Kllhn W, ltmkeS, Spillhe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs surival for patients with poor prognosis in lnternation Federnation of Gynecolog and Obsterics Ⅲc ovarian careinoma. Cancer.2001.92:2585-2591.
[28]Bruchim I, Altaras M, fisherman A. Age contrasts in clinical characteristics and pattern of care in patients wi th epithelial ovarian cancer. Gynecol Oncol,2002.86(3): 274-279
[29]Ushijima K, Ora S, Komai K, et al. Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. Int Surg, 2002,87(3):185-90.
[30]Woodward Pi, Hosseinzadeh K, Saenger JS. From the archiyes of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation. Radiographics, 2004,24(1):225-246.
[31]Obeidat B, LatimerJ. Can optimal primary cytoreduction be predicted in advanced stage epitllelial ovarian cancer? Role of preoperative serum CA125 level. Gynecol Obstet Invest,2004,57(3):153-156.
[32]Trope C, Paulsen T, Baekelandt M, et al. Controversies in surgicaltre treatment of advanced ovarian cancer. Tidsskr Nor Laegeforen,2000,120(7):824-830
[33]Hatae M, Onishi Y, Nakamura T, et al. Neoadjuvant chemotherapy for advaneed epithelial ovarian cancel. Gan To magaku Ryoho,2001,28(12):1833-1837.
[34]Vergote I. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovariall cancel. Int J Gynecol Cancer,2003,3[Supple 1]:118.
[35]Bruchim I, Altaras M, fisherman A. Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecol Oncol,2002,86(3): 274-279
[1]SchilderR, BradyMF, SpriggsD, et al. Pilot Evaluation of high-dose carbo platin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer:A Gynecologic Oncology Group Study. Gynecol Oncol.2003,88(1):3-8.
[2]李洪君,刘丽影.复发性卵巢癌的诊治现状[J].临床肿瘤学杂志.2010,12(07)：122-124.
[3]叶大风,谢幸.上皮性卵巢癌的一线化疗[J].实用妇产科杂志.2010,7(03)：：98-100.
[4]ChanYM, NgTY, HextanYS, et al. Quality of life in women treated with neoadjuvantchemo therapy for advanced ovarian cancer:A prospective long itudina lstudy. Anticancer Res.2008,11 (3):247-254.
[5]陈建国,郑伟,李爱玲.顺铂不同途径给药在卵巢癌化疗中的作用[J].癌症.2003,12(03)：24-25.
[6]周林平,罗文莉.多帕菲、卡铂联合腹腔置管治疗卵巢癌的临床观察[J].临床和实验医学杂志.2007,5(12)：89-90.
[7]吴溪.卵巢癌的化疗[J].实用妇科与产科杂志.2010,8(12)：14-16.
[8]梁凌毅.复发性卵巢癌化疗失败后有效的姑息放疗[J].国外医学.妇产科学分册.2005,6(12)：234-236.
[9]张超,崔恒,钱和年.卵巢癌化疗药物的新进展[J].中国妇产科临床杂志.2001,2(4)：245-248.
[10]王旭辉,高春英.紫杉醇联合卡铂治疗复发性上皮性卵巢癌48例临床观察[J].中国妇幼保健.2009,2(14)：56-59.
[11]张桂萍.卵巢癌化疗的进展(综述)[J].中国城乡企业卫生.2009,4(02)：78-80.
[12]杨国宏,张际绯.卵巢癌化疗的研究进展[J].牡丹江医学院学报.2010,7(02)：45-47.
[13]易晓芳,丰有吉.复发性卵巢癌的化疗进展[J].肿瘤学杂志.2008,11(02)：10-12.
[14]赵静,薛圣留,冯泽蛟.卵巢癌腹腔化疗的研究进展[J].中国实用妇科与产科杂志. 2007,23(04)：311-314.
[15]AgostinoG, AmantF, BertelootP, et al. Phase II study of gemc-itabineinre current platinum-and paclitaxel-resistant ovarian cancer. Carcinogenesis.2010,23(4):23-28.
[16]CopelandL, BookmanM,TrimbleE,etal. Clinical trials of newer regimens for treating ovarian cancer:the rationale for Gynecologic Oncology Group Protocol GOG182-ICON5. Gynecologic Oncology.2003,90(2):1-7.
[17]CantuMG, BudaA, ParmaG, et al.Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first line platinum-based regimens. J Clin Oncol. 2002,12(12):1232-1237.
[18]ChiaraS, TognoniA, Pastronel, et al. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer. Gynecologic Oncology.2004,93 (2):474-478.
[19]李贤,李斌,吴令英.脂质体阿霉素在卵巢癌二线化疗中的应用[J].国外医学.妇产科学分册.2008,14(03)：567-569.
[20]徐华瑞.联合化疗对晚期卵巢癌的疗效评价[J].中国医药导报.2008,5(26)：361-364.